216 related articles for article (PubMed ID: 12075008)
1. Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy.
Martin-Touaux E; Puech JP; Château D; Emiliani C; Kremer EJ; Raben N; Tancini B; Orlacchio A; Kahn A; Poenaru L
Hum Mol Genet; 2002 Jul; 11(14):1637-45. PubMed ID: 12075008
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation.
Nicolino MP; Puech JP; Kremer EJ; Reuser AJ; Mbebi C; Verdière-Sahuqué M; Kahn A; Poenaru L
Hum Mol Genet; 1998 Oct; 7(11):1695-702. PubMed ID: 9736771
[TBL] [Abstract][Full Text] [Related]
3. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction.
Ding E; Hu H; Hodges BL; Migone F; Serra D; Xu F; Chen YT; Amalfitano A
Mol Ther; 2002 Apr; 5(4):436-46. PubMed ID: 11945071
[TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.
Sun B; Zhang H; Benjamin DK; Brown T; Bird A; Young SP; McVie-Wylie A; Chen YT; Koeberl DD
Mol Ther; 2006 Dec; 14(6):822-30. PubMed ID: 16987711
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice.
Ding EY; Hodges BL; Hu H; McVie-Wylie AJ; Serra D; Migone FK; Pressley D; Chen YT; Amalfitano A
Hum Gene Ther; 2001 May; 12(8):955-65. PubMed ID: 11387060
[TBL] [Abstract][Full Text] [Related]
7. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
Lin CY; Ho CH; Hsieh YH; Kikuchi T
Gene Ther; 2002 May; 9(9):554-63. PubMed ID: 11973631
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
[TBL] [Abstract][Full Text] [Related]
9. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
10. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase.
Amalfitano A; McVie-Wylie AJ; Hu H; Dawson TL; Raben N; Plotz P; Chen YT
Proc Natl Acad Sci U S A; 1999 Aug; 96(16):8861-6. PubMed ID: 10430861
[TBL] [Abstract][Full Text] [Related]
11. Correction of glycogenosis type 2 by muscle-specific lentiviral vector.
Richard E; Douillard-Guilloux G; Batista L; Caillaud C
In Vitro Cell Dev Biol Anim; 2008; 44(10):397-406. PubMed ID: 18810562
[TBL] [Abstract][Full Text] [Related]
12. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
[TBL] [Abstract][Full Text] [Related]
13. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
[TBL] [Abstract][Full Text] [Related]
14. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
[TBL] [Abstract][Full Text] [Related]
15. Long-term, high-level hepatic secretion of acid α-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus.
Rastall DP; Seregin SS; Aldhamen YA; Kaiser LM; Mullins C; Liou A; Ing F; Pereria-Hicks C; Godbehere-Roosa S; Palmer D; Ng P; Amalfitano A
Gene Ther; 2016 Oct; 23(10):743-752. PubMed ID: 27367841
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase.
Fuller M; Van der Ploeg A; Reuser AJ; Anson DS; Hopwood JJ
Eur J Biochem; 1995 Dec; 234(3):903-9. PubMed ID: 8575451
[TBL] [Abstract][Full Text] [Related]
17. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.
Cresawn KO; Fraites TJ; Wasserfall C; Atkinson M; Lewis M; Porvasnik S; Liu C; Mah C; Byrne BJ
Hum Gene Ther; 2005 Jan; 16(1):68-80. PubMed ID: 15703490
[TBL] [Abstract][Full Text] [Related]
18. Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice.
Kiang A; Hartman ZC; Liao S; Xu F; Serra D; Palmer DJ; Ng P; Amalfitano A
Mol Ther; 2006 Jan; 13(1):127-34. PubMed ID: 16169280
[TBL] [Abstract][Full Text] [Related]
19. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors.
Mah C; Cresawn KO; Fraites TJ; Pacak CA; Lewis MA; Zolotukhin I; Byrne BJ
Gene Ther; 2005 Sep; 12(18):1405-9. PubMed ID: 15920463
[TBL] [Abstract][Full Text] [Related]
20. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]